Apogee Therapeutics (APGE) Competitors $39.18 -0.07 (-0.17%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. TGTX, TLX, BPMC, SRPT, AXSM, NUVL, VRNA, GRFS, KRYS, and ADMAShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics TG Therapeutics (NASDAQ:TGTX) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability. Which has stronger valuation & earnings, TGTX or APGE? TG Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329.00M22.05$12.67M$0.14326.30Apogee TherapeuticsN/AN/A-$83.99M-$3.29-11.91 Do insiders & institutionals have more ownership in TGTX or APGE? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate TGTX or APGE? TG Therapeutics currently has a consensus target price of $40.67, indicating a potential downside of 10.98%. Apogee Therapeutics has a consensus target price of $92.17, indicating a potential upside of 135.21%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, TGTX or APGE? TG Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Does the media refer more to TGTX or APGE? In the previous week, TG Therapeutics had 12 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for TG Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.58 beat TG Therapeutics' score of 1.34 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in TGTX or APGE? TG Therapeutics received 631 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 76.27% of users gave TG Therapeutics an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% Apogee TherapeuticsOutperform Votes28100.00% Underperform VotesNo Votes Is TGTX or APGE more profitable? Apogee Therapeutics has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. TG Therapeutics' return on equity of -8.32% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% Apogee Therapeutics N/A -21.81%-20.94% SummaryApogee Therapeutics beats TG Therapeutics on 9 of the 17 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.76B$2.96B$5.49B$7.97BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-16.1630.2622.6118.58Price / SalesN/A494.29397.51103.15Price / CashN/A168.6838.1834.62Price / Book5.223.166.704.26Net Income-$83.99M-$72.35M$3.22B$248.31M7 Day Performance5.76%0.81%1.26%1.34%1 Month Performance10.04%8.04%3.73%3.92%1 Year Performance-23.03%-22.95%15.82%5.33% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.226 of 5 stars$39.19-0.2%$92.17+135.2%-22.0%$1.76BN/A-16.1691News CoveragePositive NewsTGTXTG Therapeutics3.3232 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.5644 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Analyst ForecastNews CoveragePositive NewsSRPTSarepta Therapeutics4.733 of 5 stars$55.23+2.7%$158.70+187.3%-50.7%$5.36B$1.90B44.18840Upcoming EarningsAXSMAxsome Therapeutics4.8364 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.8879 of 5 stars$69.95-2.4%$115.50+65.1%+11.4%$5.01BN/A-20.1640Upcoming EarningsPositive NewsVRNAVerona Pharma2.9022 of 5 stars$60.07+2.0%$75.43+25.6%+366.5%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.8957 of 5 stars$7.01-1.0%N/A+8.1%$4.82B$7.21B5.9926,300KRYSKrystal Biotech4.9058 of 5 stars$161.91-4.0%$220.00+35.9%+10.9%$4.68B$290.52M54.15210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsADMAADMA Biologics1.4704 of 5 stars$19.64-7.8%$22.50+14.6%+265.0%$4.64B$426.45M70.14530Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies TGTX Competitors TLX Competitors BPMC Competitors SRPT Competitors AXSM Competitors NUVL Competitors VRNA Competitors GRFS Competitors KRYS Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APGE Stock Free APGE Stock Alerts